Pramipexole, a nonergot dopamine agonist, is effective against rest tremor in intermediate to advanced Parkinson's disease

Clin Neuropharmacol. Sep-Oct 1999;22(5):301-5.

Abstract

We evaluated the efficacy of the nonergot dopamine receptor agonist pramipexole in 16 patients with advanced Parkinson's disease and marked rest tremor during an "on" period. The patients were drawn from a larger placebo-controlled, double-blind, randomized trial, which was not originally designed to investigate the effect of pramipexole on tremor. Eleven patients received pramipexole. The first effects were seen with a pramipexole dose of 0.75 mg/d with a reduction of the tremor item A of Unified Parkinson's Disease Rating Scale (UPDRS III, "on" state) by 25% and of rigidity and akinesia by 22%. Under the highest dose, 4.5 mg/d, the tremor score was improved by 61% over baseline (p < 0.0056, Wilcoxon signed rank) and the sum of rigidity and akinesia items by 66% (p < 0.0038, Wilcoxon signed rank). Five patients received placebo and did not improve. Based on this sample of patients, the nonergot dopamine receptor agonist pramipexole appears to have a potent anti-rest tremor action while being effective against akinesia and rigidity.

Publication types

  • Clinical Trial
  • Controlled Clinical Trial

MeSH terms

  • Aged
  • Antiparkinson Agents / therapeutic use*
  • Benzothiazoles
  • Dopamine Agonists / therapeutic use*
  • Humans
  • Middle Aged
  • Parkinson Disease / drug therapy*
  • Pramipexole
  • Severity of Illness Index
  • Thiazoles / therapeutic use*
  • Treatment Outcome
  • Tremor / drug therapy*

Substances

  • Antiparkinson Agents
  • Benzothiazoles
  • Dopamine Agonists
  • Thiazoles
  • Pramipexole